WO2011005756A1 - Administration d'agents ciblés contre des niches de microbiote - Google Patents

Administration d'agents ciblés contre des niches de microbiote Download PDF

Info

Publication number
WO2011005756A1
WO2011005756A1 PCT/US2010/041060 US2010041060W WO2011005756A1 WO 2011005756 A1 WO2011005756 A1 WO 2011005756A1 US 2010041060 W US2010041060 W US 2010041060W WO 2011005756 A1 WO2011005756 A1 WO 2011005756A1
Authority
WO
WIPO (PCT)
Prior art keywords
bacterial
niche
pharmaceutical formulation
delivery system
group
Prior art date
Application number
PCT/US2010/041060
Other languages
English (en)
Inventor
Bernat Olle
David Aaron Putnam
Jonathan Robert Behr
W. Edward Martucci
Original Assignee
Puretech Ventures, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech Ventures, Llc filed Critical Puretech Ventures, Llc
Publication of WO2011005756A1 publication Critical patent/WO2011005756A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pulmonology (AREA)

Abstract

L'invention porte sur des procédés d'administration d'agents thérapeutiques, prophylactiques et de diagnostic à un hôte animal, l'administration de l'agent étant ciblée contre une niche bactérienne présente dans l'eau. En particulier, l'invention porte sur des systèmes d'administration capables de cibler sélectivement ou d'éviter sélectivement des niches bactériennes, les niches bactériennes étant identifiées par le rôle fonctionnel qu'elles jouent dans l'environnement de l'hôte, tel que le métabolisme de sucres, d'acides aminés ou d'agents xénobiotiques, ou par leur colonisation d'un emplacement anatomique donné de l'hôte, tel que la cavité buccale, l'intestin ou la peau. L'utilisation des compositions conduit à une altération de la composition microbienne de l'hôte associée à un état, un état de maladie ou un risque supérieur d'un état ou d'une maladie.
PCT/US2010/041060 2009-07-06 2010-07-06 Administration d'agents ciblés contre des niches de microbiote WO2011005756A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22326609P 2009-07-06 2009-07-06
US61/223,266 2009-07-06

Publications (1)

Publication Number Publication Date
WO2011005756A1 true WO2011005756A1 (fr) 2011-01-13

Family

ID=42738851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/041060 WO2011005756A1 (fr) 2009-07-06 2010-07-06 Administration d'agents ciblés contre des niches de microbiote

Country Status (1)

Country Link
WO (1) WO2011005756A1 (fr)

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054002A1 (fr) * 2011-10-12 2013-04-18 Gut Guide Oy Prévention et diagnostic de la graisse viscérale
WO2013130624A2 (fr) * 2012-02-28 2013-09-06 Cornell University Compositions probiotiques et procédés associés
WO2014010758A1 (fr) * 2012-07-13 2014-01-16 学校法人帝京平成大学 Agent antitumoral, marqueur de détection de tumeur, et agent vaccinal à usage oral
WO2014159510A1 (fr) * 2013-03-12 2014-10-02 Yale University Compositions et méthodes pour identifier des microbes liés à des anticorps sécrétoires
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9011834B1 (en) 2013-02-04 2015-04-21 Seres Health, Inc. Compositions and methods
WO2014066053A3 (fr) * 2012-10-22 2015-07-16 Polonez Therapeutics Llc Procédé de prévention et de traitement d'une infection par le clostridium difficile
WO2015184008A1 (fr) * 2014-05-27 2015-12-03 Academia Sinica Fucosidase issue de bacteroïdes et ses procédés d'utilisation
US9403855B2 (en) 2010-05-10 2016-08-02 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US9415079B2 (en) 2010-06-04 2016-08-16 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
US9642881B2 (en) 2011-12-01 2017-05-09 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US9759726B2 (en) 2014-03-27 2017-09-12 Academia Sinica Reactive labelling compounds and uses thereof
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US9816981B2 (en) 2007-03-23 2017-11-14 Academia Sinica Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10274488B2 (en) 2008-07-15 2019-04-30 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10336784B2 (en) 2016-03-08 2019-07-02 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
US10357521B2 (en) 2015-05-14 2019-07-23 University Of Puerto Rico Methods for restoring microbiota of newborns
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
CN111821427A (zh) * 2020-08-24 2020-10-27 河南省健达动保有限公司 一种预防和治疗家禽大肠杆菌病的中药制剂及制备方法
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10925953B2 (en) 2014-08-28 2021-02-23 Yale University Compositions and methods for treating an inflammatory disease or disorder
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US11254918B2 (en) 2016-12-15 2022-02-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US11884739B2 (en) 2014-05-27 2024-01-30 Academia Sinica Anti-CD20 glycoantibodies and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
WO1996009814A1 (fr) 1994-09-29 1996-04-04 Andaris Limited Microparticules sechees par pulverisation utilisees comme excipient therapeutique
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US20080057038A1 (en) * 2005-03-08 2008-03-06 Iftach Yacoby Targeted drug-carrying bacteriophages

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
WO1996009814A1 (fr) 1994-09-29 1996-04-04 Andaris Limited Microparticules sechees par pulverisation utilisees comme excipient therapeutique
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US20080057038A1 (en) * 2005-03-08 2008-03-06 Iftach Yacoby Targeted drug-carrying bacteriophages

Non-Patent Citations (54)

* Cited by examiner, † Cited by third party
Title
ADJ EI, A.; GARREN, J. PHARM. RES., vol. 7, 1990, pages 565 - 569
BACKHED ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 101, 2004, pages 15718
BAGSHAWE KD., EXPERT REV ANTICANCER THER., vol. 6, no. 10, 2006, pages 1421 - 1431
BENDTSEN JD; NIELSEN H; VON HEIJNE G; BRUNAK S, J MOL BIOL, vol. 340, 2004, pages 783 - 795
BENITA ET AL., J. PHARM. SCI., vol. 73, 1984, pages 1721 - 1724
CANI ET AL., PATHOL BIOL (PARIS)., vol. 56, no. 5, 2008, pages 305 - 9
CHEN H; HOPPER SL; CERNIGLIA CE, MICROBIOLOGY, vol. 151, 2005, pages 1433 - 1441
E. MATHIOWITZ ET AL., J. SCANNING MICROSCOPY, vol. 4, 1990, pages 329
E. MATHIOWITZ ET AL., REACTIVE POLYMERS, vol. 6, 1987, pages 275
FOWERS ET AL., J. OF DRUG TARGETING, vol. 9, no. 4, 2001, pages 281 - 294
GRICE, GENOME RES., vol. 18, no. 7, July 2008 (2008-07-01), pages 1043 - 50
HANDELSMAN ET AL., CHEM. & BIOL., vol. 5, 1998, pages 245 - 249
HAY ET AL., BR. MED. J., vol. 308, 1994, pages 295 - 298
HOLLAND ET AL., BR J DERMATOL., vol. 96, no. 6, 1977, pages 623 - 6
HOOPER ET AL., SCIENCE, vol. 291, 2001, pages 881
HOOPER ET AL., SCIENCE., vol. 292, 2001, pages 1115
HRKACH ET AL., MACROMOLECULES, vol. 28, 1995, pages 4736 - 4739
IVANOV ET AL., CELL, vol. 139, no. 3, 2009, pages 485 - 98
JANKOVIC ET AL., GENOME BIOL., vol. 8, no. 12, 2007, pages R266
KEARNEY ET AL., J GEN MICROBIOL., vol. 130, no. 4, April 1984 (1984-04-01), pages 797 - 801
L. HOVGAARD; H. BRONDSTED, CRIT. REV. THER. DRUG CARR. SYST., vol. 13, 1996, pages 185 - 223
L.R. BECK ET AL., FERTIL. STERIL., vol. 31, 1979, pages 545
LABAT-ROBERT, J.; DECAEUS, C.: "Glycoproteins du Mucus Gastrique: Structure, Fonction, et Pathologie", PATHOLOGIE ET BIOLOGIE (PARIS), vol. 24, 1979, pages 241
LABAT-ROBERT, J.; DECAEUS, C.: "Glycoproteins du Mucus Gastrique: Structure, Function, et Pathologie", PATHOLOGIE ET BIOLOGIE (PARIS), vol. 24, 1979, pages 241
LEY ET AL., NATURE, vol. 444, no. 7122, 21 December 2005 (2005-12-21), pages 1022 - 3
LINSKENS ET AL., SCAND J GASTROENTEROL., vol. 234, 2001, pages 29 - 40
MATHIOWITZ ET AL., J. APPI. POLYMER SCI., vol. 45, 1992, pages 125 - 134
MATHIOWITZ ET AL., J. APPL. POLYMER SCI., vol. 35, 1988, pages 755 - 774
MATHIOWITZ ET AL., REACTIVE POLYMERS, vol. 6, 1987, pages 275
MATHIOWITZ ET AL., REACTIVE POLYMERS, vol. 6, 1987, pages 275 - 283
MATHIOWITZ ET AL., SCANNING MICROSCOPY, vol. 4, 1990, pages 329 - 340
MATHIOWITZ; LANGER, J. CONTROLLED RELEASE, vol. 5, 1987, pages 13 - 22
PATEL M ET AL: "Therapeutic opportunities in colon-specific drug-delivery systems", CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, BEGELL HOUSE PUBLISHING INC, US, vol. 24, no. 2, 1 January 2007 (2007-01-01), pages 147 - 202, XP008109102, ISSN: 0743-4863 *
PAULINO ET AL., J. CLIN. MICROBIOL., vol. 44, 2006, pages 2933 - 2941
PAVLA KOPECKOVÁ; JINDRICH KOPECEK, MACROMOLECULAR CHEMISTRY AND PHYSICS, vol. 191, no. 9, pages 2037 - 2045
RAKOFF-NAHOUM ET AL., CELL., vol. 118, 2004, pages 229
RAM F; FRANKLIN W; CERNIGLIA CE, APPL ENVIRON. MICROBIOL., vol. 6, no. 7, 5 July 1990 (1990-07-05), pages 2146 - 2151
ROTH; JAMES, ANNU. REV. MICROBIOL., vol. 42, 1988, pages 441 - 464
S. BENITA ET AL., J. PHARM. SCI., vol. 73, 1984, pages 1721
SAFFRAN ET AL., SCIENCE, vol. 233, 1986, pages 1081
SALAMAT-MILLER N ET AL: "The use of mucoadhesive polymers in buccal drug delivery", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL LNKD- DOI:10.1016/J.ADDR.2005.07.003, vol. 57, no. 11, 3 November 2005 (2005-11-03), pages 1666 - 1691, XP025284004, ISSN: 0169-409X, [retrieved on 20051103] *
SARTOR, PROC NATL ACAD SCI U S A., vol. 28;105, no. 43, 2008, pages 16413 - 4
SCAWEN, M.; ALLEN, A.: "The Action of Proteolytic Enzymes on the Glycoprotein from Pig Gastric Mucus", BIOCHEMICAL JOURNAL, vol. 163, 1977, pages 363 - 368
SCHLOSS; HANDELSMAN, MICROBIOL. MOL. BIOL. REV., vol. 68, 2004, pages 686 - 691
SONNENBURG ET AL., NAT. IMMUNOL., vol. 5, 2004, pages 569
SPIRO, R.G.: "Glycoproteins", ANNUAL REVIEW OF BIOCHEMISTRY, vol. 39, 1970, pages 599 - 638
SPIRO, RG.: "Glycoproteins", ANNUAL REVIEW OF BIOCHEMISTRY, vol. 39, 1970, pages 599 - 63 8
STAPPENBECK ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 99, 2002, pages 15451
THOMSEN ET AL., ARCH DERMATOL., vol. 116, 1980, pages 1031 - 1034
TILL ET AL., BR. .I DERMATOL., vol. 142, 2000, pages 885 - 892
VALENTA ET AL: "The use of mucoadhesive polymers in vaginal delivery", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL LNKD- DOI:10.1016/J.ADDR.2005.07.004, vol. 57, no. 11, 3 November 2005 (2005-11-03), pages 1692 - 1712, XP025284005, ISSN: 0169-409X, [retrieved on 20051103] *
VISSER, J., POWDER TECHNOLOGY, vol. 58, 1989, pages 1 - 10
YING CHAU; FREDERICK E. TAN; ROBERT LANGER, BIOCONJUGATE CHEM., vol. 15, no. 4, 2004, pages 931 - 941
ZANEN, P.; LAMM, J.-W.J., INT. J. PHARM., vol. 114, 1995, pages 111 - 115

Cited By (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9816981B2 (en) 2007-03-23 2017-11-14 Academia Sinica Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells
US10317393B2 (en) 2007-03-23 2019-06-11 Academia Sinica Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells
US10274488B2 (en) 2008-07-15 2019-04-30 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US11267870B2 (en) 2009-12-02 2022-03-08 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US9403855B2 (en) 2010-05-10 2016-08-02 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US9874562B2 (en) 2010-05-10 2018-01-23 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US9833483B2 (en) 2010-06-04 2017-12-05 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US10588925B2 (en) 2010-06-04 2020-03-17 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US11090343B2 (en) 2010-06-04 2021-08-17 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US9415079B2 (en) 2010-06-04 2016-08-16 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US9421230B2 (en) 2010-06-04 2016-08-23 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US9808519B2 (en) 2010-06-04 2017-11-07 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US9433652B2 (en) 2010-06-04 2016-09-06 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US10322150B2 (en) 2010-06-04 2019-06-18 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US10555978B2 (en) 2010-06-04 2020-02-11 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US10092603B2 (en) 2010-06-04 2018-10-09 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US10328108B2 (en) 2010-06-04 2019-06-25 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US9642882B2 (en) 2010-06-04 2017-05-09 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US9801933B2 (en) 2010-06-04 2017-10-31 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US9827276B2 (en) 2010-06-04 2017-11-28 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US9662381B2 (en) 2010-06-04 2017-05-30 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory T cells
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
WO2013054002A1 (fr) * 2011-10-12 2013-04-18 Gut Guide Oy Prévention et diagnostic de la graisse viscérale
US10000818B2 (en) 2011-10-12 2018-06-19 Gut Guide Oy Prevention and diagnosis of visceral fat
US10238694B2 (en) 2011-12-01 2019-03-26 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US10342832B2 (en) 2011-12-01 2019-07-09 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of
US11547732B2 (en) 2011-12-01 2023-01-10 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US9649345B2 (en) 2011-12-01 2017-05-16 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US9642881B2 (en) 2011-12-01 2017-05-09 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US10183045B2 (en) 2011-12-01 2019-01-22 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US10624933B2 (en) 2011-12-01 2020-04-21 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US10835559B2 (en) 2011-12-01 2020-11-17 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US10052353B2 (en) 2011-12-01 2018-08-21 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US10058578B2 (en) 2011-12-01 2018-08-28 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US9700586B2 (en) 2012-02-28 2017-07-11 Cornell University Probiotic compositions and methods
WO2013130624A3 (fr) * 2012-02-28 2013-11-07 Cornell University Compositions probiotiques et procédés associés
WO2013130624A2 (fr) * 2012-02-28 2013-09-06 Cornell University Compositions probiotiques et procédés associés
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014010758A1 (fr) * 2012-07-13 2014-01-16 学校法人帝京平成大学 Agent antitumoral, marqueur de détection de tumeur, et agent vaccinal à usage oral
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US10214765B2 (en) 2012-08-18 2019-02-26 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
US20160250151A1 (en) * 2012-10-22 2016-09-01 Wieslaw J. Bochenek Method of prevention and treatment of clostridium difficile infection
WO2014066053A3 (fr) * 2012-10-22 2015-07-16 Polonez Therapeutics Llc Procédé de prévention et de traitement d'une infection par le clostridium difficile
US11458174B2 (en) 2012-11-23 2022-10-04 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11389490B2 (en) 2012-11-23 2022-07-19 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11458173B2 (en) 2012-11-23 2022-10-04 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10864235B2 (en) 2012-11-23 2020-12-15 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11464812B2 (en) 2012-11-23 2022-10-11 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9533014B2 (en) 2012-11-23 2017-01-03 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9028841B2 (en) 2012-11-23 2015-05-12 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11185562B2 (en) 2013-02-04 2021-11-30 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
US9446080B2 (en) 2013-02-04 2016-09-20 Seres Therapeutics, Inc. Compositions and methods
US9585921B2 (en) 2013-02-04 2017-03-07 Seres Therapeutics, Inc. Compositions and methods
US9011834B1 (en) 2013-02-04 2015-04-21 Seres Health, Inc. Compositions and methods
US10064901B2 (en) 2013-02-04 2018-09-04 Seres Therapeutics, Inc. Compositions and methods
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
US9180147B2 (en) 2013-02-04 2015-11-10 Seres Therapeutics, Inc. Compositions and methods
US10064900B2 (en) 2013-02-04 2018-09-04 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
US10967011B2 (en) 2013-02-04 2021-04-06 Seres Therapeutics, Inc. Compositions and methods
US9855303B2 (en) 2013-02-04 2018-01-02 Seres Therapeutics, Inc. Compositions and methods
US11730775B2 (en) 2013-02-04 2023-08-22 Seres Therapeutics, Inc. Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof
US11299790B2 (en) 2013-03-12 2022-04-12 Yale University Compositions and methods for identifying secretory antibody-bound microbes
US10774392B2 (en) 2013-03-12 2020-09-15 Yale University Compositions and methods for identifying secretory antibody-bound microbes
US10428392B2 (en) 2013-03-12 2019-10-01 Yale University Compositions and methods for identifying secretory antibody-bound microbes
US9758838B2 (en) 2013-03-12 2017-09-12 Yale University Compositions and methods for identifying secretory antibody-bound microbes
WO2014159510A1 (fr) * 2013-03-12 2014-10-02 Yale University Compositions et méthodes pour identifier des microbes liés à des anticorps sécrétoires
US10881696B2 (en) 2013-03-15 2021-01-05 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US11666612B2 (en) 2013-03-15 2023-06-06 Seres Therapeutics, Inc Network-based microbial compositions and methods
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US11414463B2 (en) 2013-04-10 2022-08-16 4D Pharma Research Limited Polypeptide and immune modulation
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US10111951B2 (en) 2013-09-06 2018-10-30 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10918714B2 (en) 2013-09-06 2021-02-16 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US11918612B2 (en) 2013-11-25 2024-03-05 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11266699B2 (en) 2013-11-25 2022-03-08 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US10119972B2 (en) 2014-03-27 2018-11-06 Academia Sinica Reactive labelling compounds and uses thereof
US9759726B2 (en) 2014-03-27 2017-09-12 Academia Sinica Reactive labelling compounds and uses thereof
US10023892B2 (en) 2014-05-27 2018-07-17 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
WO2015184008A1 (fr) * 2014-05-27 2015-12-03 Academia Sinica Fucosidase issue de bacteroïdes et ses procédés d'utilisation
US11319567B2 (en) 2014-05-27 2022-05-03 Academia Sinica Fucosidase from bacteroides and methods using the same
US11884739B2 (en) 2014-05-27 2024-01-30 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10618973B2 (en) 2014-05-27 2020-04-14 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
US10925953B2 (en) 2014-08-28 2021-02-23 Yale University Compositions and methods for treating an inflammatory disease or disorder
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
US10533034B2 (en) 2014-09-08 2020-01-14 Academia Sinica Human iNKT cell activation using glycolipids
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10973872B2 (en) 2014-12-23 2021-04-13 4D Pharma Research Limited Pirin polypeptide and immune modulation
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
US10357521B2 (en) 2015-05-14 2019-07-23 University Of Puerto Rico Methods for restoring microbiota of newborns
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10780134B2 (en) 2015-06-15 2020-09-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11273185B2 (en) 2015-06-15 2022-03-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11040075B2 (en) 2015-06-15 2021-06-22 4D Pharma Research Limited Compositions comprising bacterial strains
US11433106B2 (en) 2015-06-15 2022-09-06 4D Pharma Research Limited Compositions comprising bacterial strains
US10744167B2 (en) 2015-06-15 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11389493B2 (en) 2015-06-15 2022-07-19 4D Pharma Research Limited Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US10864236B2 (en) 2015-06-15 2020-12-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11331352B2 (en) 2015-06-15 2022-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
US11058732B2 (en) 2015-11-20 2021-07-13 4D Pharma Research Limited Compositions comprising bacterial strains
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10336784B2 (en) 2016-03-08 2019-07-02 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US10610549B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Composition comprising bacterial strains
US10960031B2 (en) 2016-07-13 2021-03-30 4D Pharma Plc Compositions comprising bacterial strains
US10967010B2 (en) 2016-07-13 2021-04-06 4D Pharma Plc Compositions comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US10898526B2 (en) 2016-12-12 2021-01-26 4D Pharma Plc Compositions comprising bacterial strains
US10543238B2 (en) 2016-12-12 2020-01-28 4D Pharma Plc Compositions comprising bacterial strains
US11254918B2 (en) 2016-12-15 2022-02-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
US11376284B2 (en) 2017-05-22 2022-07-05 4D Pharma Research Limited Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11382936B2 (en) 2017-05-22 2022-07-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11660319B2 (en) 2017-06-14 2023-05-30 4D Pharma Research Limited Compositions comprising bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11779613B2 (en) 2017-06-14 2023-10-10 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CN111821427A (zh) * 2020-08-24 2020-10-27 河南省健达动保有限公司 一种预防和治疗家禽大肠杆菌病的中药制剂及制备方法

Similar Documents

Publication Publication Date Title
WO2011005756A1 (fr) Administration d'agents ciblés contre des niches de microbiote
US10130695B2 (en) Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
US20170165201A1 (en) Ph-responsive mucoadhesive polymeric encapsulated microorganisms
JP2020097625A (ja) 経口投与型コルチコステロイド組成物
ES2761341T3 (es) Una formulación de fármaco de liberación retardada
Hejazi et al. Chitosan-based gastrointestinal delivery systems
JP6464142B2 (ja) プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー
TWI351969B (en) Azithromycin dosage forms with reduced side effect
CN104666248B (zh) 提供立即释放模式和持续释放模式双重作用的吸入制剂
EP2026768B1 (fr) Formulation pharmaceutique comprenant des unités multiples
HU209243B (en) Long acting coated compositions
US9539334B2 (en) Orally dissolving thin films containing allergens and methods of making and use
NZ565960A (en) Controlled release pharmaceutical compositions for acid labile drugs
JP2007533755A (ja) 高分子量ｐｅｇ様化合物を含む治療薬送達システム
JP6441828B2 (ja) 安定なグルコキナーゼ活性化剤組成物
EP3581176A1 (fr) Nanoparticules de zéine de type noyau-enveloppe pour encapsulation de composés, leur procédé de préparation et leurs utilisations
JPH08509958A (ja) ビサコジル剤形
JP2016535030A (ja) 遅延放出性薬物製剤
JP5553132B2 (ja) 粒子状医薬組成物
Brotons-Canto et al. Mannosylated nanoparticles for oral immunotherapy in a murine model of peanut allergy
Carmen Chifiriuc et al. Biomedical applications of natural polymers for drug delivery
Batchelor Bioadhesive dosage forms for esophageal drug delivery
WO2019142799A1 (fr) Gélule pour traiter une colite ulcéreuse
TWI526221B (zh) 果糖吸收不良之治療技術
BR112021010914A2 (pt) Formulação de fármaco de liberação retardada que compreende uma camada externa com um polímero enzimaticamente degradável, sua composição e seu método de fabricação

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10730684

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10730684

Country of ref document: EP

Kind code of ref document: A1